Company intelligence / Profile preview
Halozyme Therapeutics, Inc.
San Diego, California, United Stateshalozyme.com ↗
- Ownership
- Public · HALO
- Employees
- ~400
- Development stage
- Commercial
01
Overview
Halozyme has a robust commercial portfolio centered around its proprietary ENHANZE® drug delivery technology. This platform enables subcutaneous administration of biologics that are typically given intravenously, improving patient convenience and potentially outcomes. The company’s technology has been validated by multiple regulatory approvals in partnership with major pharmaceutical companies. For example, in December 2024 the FDA approved Opdivo Qvantig™—a co-formulation of nivolumab and hyaluronidase-nvhy using ENHANZE—for all previously approved adult solid tumor IV Opdivo indications[3].
- Therapeutic areas
- OtherMen's HealthOncology
- Modalities
- Recombinant human enzymes (notably rHuPH20)Drug delivery technologies for biologics and small molecules
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $12.7B
- Total revenue
- $481M
- Enterprise value
- $14.6B
Beyond the preview
Go deeper on Halozyme Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halozyme Therapeutics, Inc..